People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eargo, Inc. | — | Other Health Care | Series C | $187.4M | $1.8B | 2018 |
| Otolith Sound, Inc. | — | Biotechnology | Series B | $30.9M | $33.8M | 2024 |
Raphael Michel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Raphael Michel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Juliet Bakker | 1 | 9 |
| Peter Bisgaard | 1 | 9 |
| David Wu | 1 | 7 |
| Geoff Pardo | 1 | 6 |
| Anthony Aiudi | 1 | 4 |
| Dan Wagner | 1 | 4 |
| Josh Makower | 1 | 3 |
| Tak Cheung | 1 | 3 |
| Christian Gormsen | 1 | 2 |
| Kevin Franck | 1 | 1 |
| Jon Akers | 1 | 1 |
| Didier Depireux | 1 | 1 |
| Tom Hardart | 1 | 1 |
| Thomas Hardart | 1 | 1 |
| John Daggitt | 1 | 1 |
| Adam Laponis | 1 | 1 |
| Peter Biisgard | 1 | 1 |
| William Brownie | 1 | 1 |
| David Tuxen Wu | 1 | 1 |
| Raphael Tuxen Michel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.